AIDS Vaccine is the largest global scientific conference focused exclusively on AIDS vaccine research. Hosted annually by the Global HIV Vaccine Enterprise and local partners, AIDS Vaccine brings together the scientific minds to exchange the latest research findings, explore new ideas, educate future leaders and engage a diverse community to help further research to develop a safe and effective HIV vaccine.
View the program here.
AIDS Vaccine Research: The latest news and conference details
This webinar featured leaders in the field providing updates on ongoing and planned efficacy trials, along with a review of the science behind neutralizing antibody research.
For background on each of these issues check out AVAC’s fact sheet series, AIDS Vaccine Science for Busy Advocates.
AVAC AT AIDS VACCINE 2012
Symposia 04: Cross-cutting Issues in Clinical Trial Design
In a symposium on cross-cutting issues in trial design, presenters offered ideas on whether and how PrEP may be added to ongoing and planned AIDS vaccine trials, and the ethical and practical challenges of defining the standard of prevention offered to trial participants as new strategies are identified. Slides are available:
- PrEP and Vaccines: When and how to respond to positive data—Mitchell Warren
- Evolving Standards of Prevention and Implications for Future Trials—Douglas R. Wassenaar
- Combination Prevention: Scaling up delivery while accelerating discovery, lessons from medical male circumcision in Kenya—Kawango Agot (coming soon)
- Combination Prevention: Designing and implementing a new era of trials—Ruanne V. Barnabas
- Combination Prevention: A community perspective on complex trial results and design—Matthew Rose
Good Participatory Practice (GPP) Guidelines
- Monitoring and Evaluation of Community and Stakeholder Engagement in Research—Stacey Hannah, AVAC and Prince Bahati, IAVI
- An assessment of GPP Guidelines at HIV prevention research clinical centers in Eastern and Southern Africa—Prince Bahati, IAVI and Stacey Hannah, AVAC
- Global Implementation of GPP Guidelines for Biomedical HIV Prevention Research: Charting progress and setting milestones—AVAC
HIV Vaccines & Microbicides Resource Tracking
- Preventative HIV Vaccine Research and Development: Resource trends 2000-2011—HIV Vaccines & Microbicides Resource Tracking Working Group
Each of the sessions in the conference program was webcast—see the full list here.
Our suggested webcast viewing is available here.
Additional coverage of AIDS Vaccine 2012 will appear in the forthcoming issue of Px Wire.